Invitation to Idorsia's full year financial results 2022
Idorsia will publish its full year financial results 2022 on Tuesday February 7, 2023, at 07:00 CET An investor conference call and webcast will be......
Idorsia submits European marketing authorisation
The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained......